No profile data available.
Elutia Inc. (ELUT) is a healthcare company in the various healthcare equipment manufacturing industry, based in Gaithersburg, United States, with about 25 full-time employees.
It reported revenue of $12.29 million for fiscal year 2025, down 49.6% from fiscal year 2024, and net income of $53.38 million. Its largest business segment, Women's Health, brought in 74% of segment revenue in fiscal year 2025. Its market capitalization was $36.45 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
Elutia reported $12.29 million in revenue for fiscal year 2025, down 49.6% from $24.38 million in fiscal year 2024.
Women's Health, with $9.14 million or 74% of segment revenue in fiscal year 2025. Next: Cardiovascular (26%).
$36.45 million as of October 9, 2026.
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include AngioDynamics, Inc. (ANGO), Profound Medical Corp. (PROF), Harvard Bioscience, Inc. (HBIO), Aethlon Medical, Inc. (AEMD).